feedback

Course Director

Professor Peter Schmid, FRCP, MD, PhD
Professor Peter Schmid, FRCP, MD, PhD

Centre for Experimental Cancer Medicine
Barts Cancer Institute, St Bartholomew’s Hospital
London, England, United Kingdom

Faculty

Leisha A. Emens
Leisha A. Emens, MD, PhD

Women’s Cancer Research Center
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

Heather L. McArthur
Heather L. McArthur, MD, MPH

Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California

Accredited by

Medical Learning Institute, Inc.

Activity Description

Tremendous advances have been made in the treatment of many other subtypes of breast cancer, but treatment of triple-negative breast cancer (TNBC) has remained challenging. However, recent developments suggest that we are on the brink of a new era in TNBC therapy that will bring the novel class of cancer immunotherapies to this population of patients. What is the most rational way and optimal setting to use cancer immunotherapies? How can we maximize their benefits so that more patients with TNBC would benefit from them?

In this CME/MOC/CNE-accredited PeerView MasterClass on-demand activity, our expert panel discusses the biologic rationale for the use of cancer immunotherapies in breast cancer in general and TNBC specifically, as well as evolving evidence supporting the use of immune checkpoint inhibitors in advanced/metastatic and early-stage TNBC in neoadjuvant and adjuvant settings. Additionally, the panel focuses on patient/tumor evaluation and candidate selection for immunotherapies, using current and novel biomarkers to guide clinical decisions in early-stage and advanced disease, the importance of being aware of potential immune-related adverse events and how to diagnose/manage them, and the need for close collaboration among oncologists, breast surgeons, pathologists, and other professionals involved in the management of patients with breast cancer. Illustrative case studies and clinical scenarios discussed during the Practicum segment provide further guidance on best practices for the use and integration of immunotherapies into the treatment arsenal for patients with TNBC in real-world, clinical practice settings.

Target Audience

The activity has been designed to meet the educational needs of oncologists, pathologists, surgeons, nurses, and other professionals involved in the management of patients with breast cancer.

Educational Objectives

Upon completion of this activity, participants will be able to:
  • Describe the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC) specifically, and in breast cancer more broadly, including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies (eg, chemotherapies, other immunotherapies, PARP inhibitors and other targeted agents, surgery, radiation, etc) that may enhance immunogenicity and improve outcomes
  • Discuss biomarkers that may have utility in guiding and refining clinical decisions regarding the selection of appropriate candidates for immune-based and other therapies in TNBC, and the nuances of testing for these biomarkers in practice
  • Analyze efficacy, safety, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including metastatic, locally advanced, and early-stage resectable disease
  • Integrate immune checkpoint inhibitors and/or other effective treatment modalities into management plans of patients with TNBC based on the latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, biomarker testing results, and patient needs/preferences

Providership, Credit, and Support


This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by independent educational grants from Celgene Corporation, Eisai Inc., and Merck & Co., Inc.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Continuing Nursing Education

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.5 contact hour(s).

Faculty Disclosures

Chair
Professor Peter Schmid, FRCP, MD, PhD
Lead, Centre for Experimental Cancer Medicine
Barts Cancer Institute, St Bartholomew’s Hospital
London, England, United Kingdom

Professor Peter Schmid, FRCP, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim International GmbH; Celgene Corporation; Eisai Co., Ltd.; F. Hoffmann-La Roche Ltd (himself and spouse); Genentech, Inc. (spouse); Merck & Co., Inc.; Novartis AG; Pfizer Inc.; and Puma Biotechnology, Inc.
Grant/Research Support from Astellas Pharma Inc.; AstraZeneca; F. Hoffmann-La Roche Ltd; Genentech, Inc.; OncoGenex Pharmaceuticals, Inc.; and Novartis AG.

Faculty
Leisha A. Emens, MD, PhD
Professor of Medicine
Director of Translational Immunotherapy
for the Women’s Cancer Research Center
Co-Leader, Cancer Immunology and Immunotherapy Program
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

Leisha A. Emens, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol-Myers Squibb; Celgene Corporation; eTheRNA immunotherapies NV; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Gritstone Oncology; MacroGenics, Inc.; Medimmune; MolecuVax; Novartis Pharmaceuticals Corporation; Peregrine Pharmaceuticals; Replimune Group Inc.; Syndax Pharmaceuticals, Inc.; and Vaccinex, Inc.
Grant/Research Support from Aduro Biotech; AstraZeneca; Breast Cancer Research Foundation; Bristol-Myers Squibb; Corvus Pharmaceuticals; Department of Defense; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; HeritX; MaxCyte, Inc.; Merck & Co., Inc.; National Cancer Institute; NSABP Foundation; and Translational Breast Cancer Research Consortium.
Honoraria from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; Celgene Corporation; Gritstone Oncology; Medimmune; Peregrine Pharmaceuticals; Replimune Group Inc.; Syndax Pharmaceuticals, Inc.; and Vaccinex, Inc.
Other financial interest/relationship for Global Clinical Trial Steering Committees/Data Safety Monitoring Boards for Ambiance; Genentech, Inc./F. Hoffmann-La Roche Ltd; and Trio Pharmaceuticals, Inc./Syndax Pharmaceuticals, Inc. Royalties for Aduro IND Licensing/vaccine. Board of Directors for the Society for Immunotherapy of Cancer (SITC), non-profit.

Heather L. McArthur, MD, MPH
Medical Director, Breast Oncology
Hematology/Oncology
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California

Heather L. McArthur, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Company, Limited; Genentech, Inc.; Immunomedics; Merck & Co., Inc.; Pfizer Inc.; and Puma Biotechnology, Inc.
Grant/Research Support from Grant/Research Support from: AstraZeneca; Bristol-Myers Squibb; BTG International Ltd.; MedImmune; and Merck & Co., Inc.

Planning Committee Disclosures

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, MLI, has nothing to disclose.

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Shaina Rozell, MD, MPH
Stacy L. Sims, MSN, RN, CMCN

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC/CNE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive MOC/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/MOC/CNE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.